Sign up to save your podcasts
Or
Share Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma
CME credits: 0.25
Valid until: 09-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/preventing-disease-recurrence-adjuvant-therapy-stage-iibiic-melanoma/15392/
The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 09-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/preventing-disease-recurrence-adjuvant-therapy-stage-iibiic-melanoma/15392/
The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.
=